Advertisement
UK markets closed

  • FTSE 100

    8,213.49
    +41.34 (+0.51%)
     

  • FTSE 250

    20,164.54
    +112.21 (+0.56%)
     

  • AIM

    771.53
    +3.42 (+0.45%)
     

  • GBP/EUR

    1.1652
    -0.0031 (-0.26%)
     

  • GBP/USD

    1.2546
    +0.0013 (+0.11%)
     

  • Bitcoin GBP

    50,761.52
    +463.81 (+0.92%)
     

  • CMC Crypto 200

    1,326.31
    +49.33 (+3.86%)
     

  • S&P 500

    5,127.79
    +63.59 (+1.26%)
     

  • DOW

    38,675.68
    +450.02 (+1.18%)
     

  • CRUDE OIL

    77.99
    -0.96 (-1.22%)
     

  • GOLD FUTURES

    2,310.10
    +0.50 (+0.02%)
     

  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     

  • HANG SENG

    18,475.92
    +268.79 (+1.48%)
     

  • DAX

    18,001.60
    +105.10 (+0.59%)
     

  • CAC 40

    7,957.57
    +42.92 (+0.54%)
     
BRANDS:

Meet one of the UK’s largest unknown start-ups

Video editing platform Veed has grown to 10 million users

U.S. settles charges related to Actavis' Warner Chilcott buy

Reuters - UK Focus

WASHINGTON, Sept 27 (Reuters) - The U.S. Federal Trade Commission on Friday said it settled charges that generic drugmaker Actavis Inc (NYSE: ACT - news) 's proposed $8.5 billion purchase of Warner Chilcott Plc (NasdaqGS: WCRX - news) would be anticompetitive.

As part of the proposed settlement, Actavis has agreed to sell all rights and assets to three oral contraceptives and an osteoporosis treatment, the commission said.

The drugs involved are generic Femcon FE; Loestrin 24 FE and its generic equivalents; and Lo Loestrin FE and its generic equivalents, all contraceptives; and Atelvia and its generic equivalents.